REG - Intelligent Ultrasnd - Intelligent Ultrasound signs research agreement

Intelligent UltrasoundAnnouncement

07/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231107:nRSG5510Sa&default-theme=true

RNS Number : 5510S  Intelligent Ultrasound Group PLC  07 November 2023

Intelligent Ultrasound signs research agreement with University of Dundee to
develop AI-based diagnostic tools for liver disease

 

 

PRESS RELEASE 07 November 2023: Intelligent Ultrasound Group plc (AIM: IUG),
the 'classroom to clinic' ultrasound company, specialising in artificial
intelligence (AI) software and simulation, is pleased to announce that it has
signed a research agreement with the University of Dundee to initiate the
first phase of proof-of-concept work to develop AI-based tools for screening
patients with liver disease.

 

Utilising the comprehensive archive comprising over one million ultrasound
images from approximately 50,000 patients from the University of Dundee and
NHS Tayside, the Intelligent Ultrasound team intends to create
machine-learning models that make it easier to stage liver disease and monitor
disease progression.

 

The agreement, which is mainly royalty-based, will allow Intelligent
Ultrasound to develop ultrasound-based AI tools with the potential to support
clinicians in the clinical management of metabolic dysfunction-associated
steatotic liver disease (MASLD) and its advanced form, metabolic
dysfunction-associated steatohepatitis (MASH). MASLD is the leading cause of
liver disease and is closely related to obesity, the rates of which are
rising. 1  (#_ftn1) Monitoring MASLD is important as patients in the early
stages of the disease may be able to reduce the effects on their liver with
dietary and lifestyle changes if caught in time. 2  (#_ftn2)

 

Around 30% of the world's population have MASLD, and by 2030 it is expected
that healthcare systems will need to accurately stage the disease to allow
them to target treatment. 3  (#_ftn3) As current methods for diagnosis are
either invasive, costly, or inaccurate, it is hoped that AI-based ultrasound
may prove to be a cost-effective point of care technique that can give
clinicians the answers they need.

 

Nicholas Sleep, COO at Intelligent Ultrasound said:

 

"We are very pleased to be working with Prof. John Dillon at the University of
Dundee on this exciting project. John is a world-renowned hepatologist, having
played a major role in introducing Hepatitis C screening in Scotland. His
team's clinical experience, combined with the richness of the Dundee dataset,
create a strong pairing with Intelligent Ultrasound's expertise in creating
healthcare AI solutions. This is a key longer-term step for us as we look to
build our fourth AI ultrasound platform and we have high hopes for this
proof-of-concept work."

 

Professor John Dillon, Professor of Hepatology and Gastroenterology, Clinical
Professor (Teaching and Research) of Hepatology and Gastroenterology,
Molecular and Clinical Medicine at the University of Dundee said:

 

"One of the largest challenges facing us in medicine today is how to stratify
a disease - MASLD - that affects 30% of the global population and find the
much smaller group with MASH who are at high risk of complications. I am
optimistic that by working with the AI specialists at Intelligent Ultrasound,
we may be able to make the widely available ultrasound scanning facilities
much more useful by adding the ability to differentiate MASH from MASLD
patients."

 

 

ENDS

 

Enquiries:

 

 Intelligent Ultrasound Group plc   www.intelligentultrasound.com (http://www.intelligentultrasound.com)
 Stuart Gall, CEO                   Tel: +44 (0)29 2075 6534
 Helen Jones, CFO

 Cavendish Securities Plc

 (Nominated advisor and broker)
 Giles Balleny (Corporate Finance)  Tel: +44 (0)20 7397 8900

 Dale Bellis (Sales)

 

  TB Cardew - PR Advisors   Intelligentultrasound@tbcardew.com (mailto:Intelligentultrasound@tbcardew.com)

  Ed Orlebar                Tel: +44 (0)7738 724630
  Allison Connolly                                                    Tel: +44 (0)7587 453955
  Emma Pascoe-Watson                                                  Tel: +44 (0)7774 620415
  Hero Kurzeja                                                        Tel: +44 (0)7827 130430

 

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,500 simulators have been sold to over 750 medical
institutions around the world.

 

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis technology.
Current products on the market utilising this technology are GE
Healthcare's SonoLyst software that is incorporated in their Voluson Expert
22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound-guided needling by providing the user with real-time AI-based
anatomy highlighting for a range of medical procedures; and NeedleTrainer
that teaches real-time ultrasound-guided needling and incorporates ScanNav
Anatomy PNB.

 

www.intelligentultrasound.com (http://www.intelligentultrasound.com/)

 

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the
FDA, but is not available for sale in any other territory requiring government
approval for this type of product.

 

 

 1  (#_ftnref1) Fatty Liver Disease (liverfoundation.org)
(https://liverfoundation.org/about-your-liver/facts-about-liver-disease/fatty-liver-disease/)

 2  (#_ftnref2) NAFLD, NASH and fatty liver disease - British Liver Trust
(https://britishlivertrust.org.uk/information-and-support/liver-conditions/non-alcohol-related-fatty-liver-disease/)

 3  (#_ftnref3) "The global epidemiology of nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review".
Heptaology, April 2023, 77(4), 1335-1347

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUPGQWGUPWGMQ